Madrigal Pharmaceuticals Reports 2017 First Quarter Financial Results
May 11, 2017 17:00 ET
|
Madrigal Pharmaceuticals, Inc.
- Phase 2 clinical studies of MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, are underway in patients with non-alcoholic steatohepatitis (NASH) and familial...
Madrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Update on Lead Clinical-stage Compound, MGL-3196
April 03, 2017 07:30 ET
|
Madrigal Pharmaceuticals, Inc.
- MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, has the potential to treat NASH (non-alcoholic steatohepatitis) and familial hypercholesterolemia (FH) - -...
Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
February 23, 2017 08:15 ET
|
Madrigal Pharmaceuticals, Inc.
-- HeFH is the most common dominantly inherited disease, present in up to 1 in 200 people, in which there is a life-long burden of high LDL cholesterol build up requiring aggressive lipid lowering...
Madrigal Reports Third Quarter 2016 Financial Results
November 14, 2016 16:30 ET
|
Madrigal Pharmaceuticals, Inc.
- Successfully Completed Merger and Transition to Public Company - - Initiated Phase II study in NASH - - Out-licensed non-core asset HSP90 to Tarveda Therapeutics - WEST CONSHOHOCKEN, Pa., Nov. ...
Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Non-alcoholic Steatohepatitis (NASH)
October 20, 2016 07:30 ET
|
Madrigal Pharmaceuticals, Inc.
-- Study expected to provide proof-of-concept data in NASH for the first liver-directed, thyroid hormone receptor (THR) ß-selective agonist – -- Primary endpoint is the reduction of liver fat,...
Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform
September 19, 2016 07:30 ET
|
Madrigal Pharmaceuticals, Inc.
- PEN-866 positioned to begin clinical trials in 2017 – - Total potential payments to Madrigal may exceed $249 Million – CONSHOHOCKEN, Pa. and WATERTOWN, Mass., Sept. 19, 2016 (GLOBE NEWSWIRE) --...
Richard S. Levy, M. D., Appointed to Madrigal Board of Directors
August 11, 2016 07:30 ET
|
Madrigal Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
July 22, 2016 11:30 ET
|
Synta Pharmaceuticals Corp
FORT WASHINGTON, Pa., July 22, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of...